

# Juan Montoro GÃ³mez

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7192953/publications.pdf>

Version: 2024-02-01

21  
papers

264  
citations

1163117

8  
h-index

996975

15  
g-index

21  
all docs

21  
docs citations

21  
times ranked

405  
citing authors

#	ARTICLE	IF	CITATIONS
1	<sc>SARS-CoV-2</sc> reactive antibody detection after <sc>SARS-CoV-2</sc> vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group. American Journal of Hematology, 2022, 97, 30-42.	4.1	52
2	Clinical Effectiveness of Influenza Vaccination After Allogeneic Hematopoietic Stem Cell Transplantation: A Cross-sectional, Prospective, Observational Study. Clinical Infectious Diseases, 2019, 68, 1894-1903.	5.8	36
3	SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders. Journal of Hematology and Oncology, 2022, 15, 54.	17.0	26
4	Community-acquired respiratory virus lower respiratory tract disease in allogeneic stem cell transplantation recipient: Risk factors and mortality from pulmonary virus-bacterial mixed infections. Transplant Infectious Disease, 2018, 20, e12926.	1.7	24
5	Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors. Bone Marrow Transplantation, 2020, 55, 2147-2159.	2.4	24
6	Ex Vivo T Cell-Depleted Hematopoietic Stem Cell Transplantation for Adult Patients with Acute Myelogenous Leukemia in First and Second Remission: Long-Term Disease-Free Survival with a Significantly Reduced Risk of Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2020, 26, 323-332.	2.0	19
7	Incidence, risk factors, and outcome of pulmonary invasive fungal disease after respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients. Transplant Infectious Disease, 2019, 21, e13158.	1.7	17
8	Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study. Bone Marrow Transplantation, 2021, 56, 1919-1928.	2.4	13
9	Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia. Bone Marrow Transplantation, 2022, 57, 1389-1398.	2.4	10
10	The clinical benefit of instituting a prospective clinical community-acquired respiratory virus surveillance program in allogeneic hematopoietic stem cell transplantation. Journal of Infection, 2020, 80, 333-341.	3.3	7
11	Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients. Annals of Hematology, 2022, 101, 2053-2067.	1.8	7
12	Comparison of transfusion requirements in adult patients undergoing Haploidentical or single-unit umbilical cord blood stem cell transplantation. European Journal of Haematology, 2019, 103, 172-177.	2.2	5
13	Common seasonal respiratory virus infections in allogeneic stem cell transplant recipients during the SARS-COV-2 pandemic. Bone Marrow Transplantation, 2021, 56, 2212-2220.	2.4	5
14	Invasive fungal disease in patients undergoing umbilical cord blood transplantation after myeloablative conditioning regimen. European Journal of Haematology, 2019, 102, 331-340.	2.2	4
15	Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft-versus-host disease prophylaxis. EJHaem, 2021, 2, 236-248.	1.0	4
16	Community acquired respiratory virus infections in adult patients undergoing umbilical cord blood transplantation. Bone Marrow Transplantation, 2020, 55, 2261-2269.	2.4	3
17	Risk factors and outcomes of follicular lymphoma after allogeneic hematopoietic stem cell transplantation using HLA-matched sibling, unrelated, and haploidentical-related donors. Bone Marrow Transplantation, 2021, 56, 992-996.	2.4	3
18	Ex vivo T-cell depletion vs post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. European Journal of Haematology, 2021, 106, 114-125.	2.2	2

#	ARTICLE	IF	CITATIONS
19	Extracorporeal photopheresis vs standard therapies for steroidâ€refractory chronic graftâ€vsâ€host disease: Pharmacoeconomic assessment of hospital resource use in Spain. Journal of Clinical Apheresis, 2021, 36, 612-620.	1.3	2
20	Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis. Leukemia and Lymphoma, 2020, 61, 1823-1832.	1.3	1
21	Male genital GvHD: a hidden complication following haematopoietic stem cell transplantation. British Journal of Haematology, 2020, 191, 12-12.	2.5	0